143007-15-2

Basic information

• Product Name: 2-chloro-6,7-difluoroquinoxaline
• Synonyms: 2-chloro-6,7-difluoroquinoxaline
• CAS NO: 143007-15-2
• Molecular Formula: C₈H₃ClF₂N₂
• Molecular Weight: 200.57
• Product Categories: CHIRAL CHEMICALS
• Mol File: 143007-15-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 263℃
• Flash Point: 113℃
• Appearance: /
• Density: 1.538
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: 2-8°C
• PKA: -3.15±0.30(Predicted)
• CAS DataBase Reference: 2-chloro-6,7-difluoroquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-6,7-difluoroquinoxaline(143007-15-2)
• EPA Substance Registry System: 2-chloro-6,7-difluoroquinoxaline(143007-15-2)

Safety Data

• Hazardous Substances Data: 143007-15-2(Hazardous Substances Data)

Usage

General Description

2-Chloro-6,7-difluoroquinoxaline is a chemical compound with the molecular formula C8H4ClF2N2. It is a heterocyclic aromatic compound containing a quinoxaline ring with a chlorine atom at position 2 and two fluorine atoms at positions 6 and 7. 2-chloro-6,7-difluoroquinoxaline is commonly used as a building block or intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has the potential for various applications in the fields of drug discovery and development, as well as agricultural and industrial chemicals. Additionally, 2-chloro-6,7-difluoroquinoxaline has been studied for its potential biological activities and therapeutic properties. However, it is important to handle this chemical with proper safety precautions due to its potential hazards.

InChI:InChI=1/C8H3ClF2N2/c9-8-3-12-6-1-4(10)5(11)2-7(6)13-8/h1-3H

Upstream product

• 137690-08-5 6,7-difluoroquinoxaline-2-ol 
• 76179-40-3 2-amino-4,5-difluoroaniline 
• 137690-08-5 6,7-difluoroquinoxaline-2(1H)-one 

Downstream Products

• 1030377-40-2 6,7-difluoro-2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}quinoxaline 
• 1163123-26-9 C₂₁H₁₇F₅N₄O 
• 1384120-93-7 ((1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl)(4-methyl-[1,1'-biphenyl]-2-yl)methanone 
• 476374-15-9 (S)-2-{2-[4-(6,7-Difluoro-quinoxalin-2-ylamino)-phenyl]-acetylamino}-pentanedioic acid diethyl ester 
• 476374-09-1 [4-(6,7-difluoro-quinoxalin-2-ylamino)-phenyl]-acetic acid 
• 709638-76-6 2-ethoxy-6,7-difluoroquinoxaline 
• 709638-28-8 [4-(6,7-difluoro-quinoxalin-2-yloxy)-phenyl]-acetic acid methyl ester 
• 476374-04-6 [4-(6,7-difluoro-quinoxalin-2-ylamino)-phenyl]-acetic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach

Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach. Structure–activity relationship optimization allowed us not only to improve the antagonistic potency on both orexin 1 and orexin 2 receptors (Ox1 and Ox2, respectively), but also to increase metabolic stability in human liver microsomes (HLM), decrease time-dependent inhibition of cytochrome P450 (CYP) 3A4, and decrease P-glycoprotein (Pgp)-mediated efflux. Compound 80 c [{(1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl}(4-methyl-[1,1′-biphenyl]-2-yl)methanone] is a potent and selective DORA that inhibits the stimulating effects of orexin peptides OXA and OXB at both Ox1 and Ox2. In calcium-release assays, 80 c was found to exhibit an insurmountable antagonistic profile at both Ox1 and Ox2, while displaying a sleep-promoting effect in rat and dog models, similar to that of the benchmark compound suvorexant.

Substituted diazepan orexin receptor antagonists

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.